Hereditary Angioedema Market Report

Global Hereditary Angioedema Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 02, 2022
  • PAGES：220
  • REPORT CODE：GMM790360
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Hereditary Angioedema market report explains the definition, types, applications, major countries, and major players of the Hereditary Angioedema market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Shire plc

    • CSL Limited

    • BioCryst Pharmaceuticals Inc

    • iBio Inc

    • Ionis Pharmaceuticals Inc

    • Pharming Group NV

    By Type:

    • C1 Esterase Inhibitor

    • Kallikrein Inhibitor

    • Selective Bradykinin B2 Receptor Antagonist

    By End-User:

    • Retail Pharmacies

    • Hospital Pharmacies

    • Online Pharmacies

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Hereditary Angioedema Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Hereditary Angioedema Outlook to 2028- Original Forecasts

    • 2.2 Hereditary Angioedema Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Hereditary Angioedema Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Hereditary Angioedema Market- Recent Developments

    • 6.1 Hereditary Angioedema Market News and Developments

    • 6.2 Hereditary Angioedema Market Deals Landscape

    7 Hereditary Angioedema Raw Materials and Cost Structure Analysis

    • 7.1 Hereditary Angioedema Key Raw Materials

    • 7.2 Hereditary Angioedema Price Trend of Key Raw Materials

    • 7.3 Hereditary Angioedema Key Suppliers of Raw Materials

    • 7.4 Hereditary Angioedema Market Concentration Rate of Raw Materials

    • 7.5 Hereditary Angioedema Cost Structure Analysis

      • 7.5.1 Hereditary Angioedema Raw Materials Analysis

      • 7.5.2 Hereditary Angioedema Labor Cost Analysis

      • 7.5.3 Hereditary Angioedema Manufacturing Expenses Analysis

    8 Global Hereditary Angioedema Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Hereditary Angioedema Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Hereditary Angioedema Export by Region (Top 10 Countries) (2017-2028)

    9 Global Hereditary Angioedema Market Outlook by Types and Applications to 2022

    • 9.1 Global Hereditary Angioedema Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global C1 Esterase Inhibitor Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Kallikrein Inhibitor Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Selective Bradykinin B2 Receptor Antagonist Consumption and Growth Rate (2017-2022)

    • 9.2 Global Hereditary Angioedema Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Retail Pharmacies Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Online Pharmacies Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Hereditary Angioedema Market Analysis and Outlook till 2022

    • 10.1 Global Hereditary Angioedema Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Hereditary Angioedema Consumption (2017-2022)

      • 10.2.2 Canada Hereditary Angioedema Consumption (2017-2022)

      • 10.2.3 Mexico Hereditary Angioedema Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Hereditary Angioedema Consumption (2017-2022)

      • 10.3.2 UK Hereditary Angioedema Consumption (2017-2022)

      • 10.3.3 Spain Hereditary Angioedema Consumption (2017-2022)

      • 10.3.4 Belgium Hereditary Angioedema Consumption (2017-2022)

      • 10.3.5 France Hereditary Angioedema Consumption (2017-2022)

      • 10.3.6 Italy Hereditary Angioedema Consumption (2017-2022)

      • 10.3.7 Denmark Hereditary Angioedema Consumption (2017-2022)

      • 10.3.8 Finland Hereditary Angioedema Consumption (2017-2022)

      • 10.3.9 Norway Hereditary Angioedema Consumption (2017-2022)

      • 10.3.10 Sweden Hereditary Angioedema Consumption (2017-2022)

      • 10.3.11 Poland Hereditary Angioedema Consumption (2017-2022)

      • 10.3.12 Russia Hereditary Angioedema Consumption (2017-2022)

      • 10.3.13 Turkey Hereditary Angioedema Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Hereditary Angioedema Consumption (2017-2022)

      • 10.4.2 Japan Hereditary Angioedema Consumption (2017-2022)

      • 10.4.3 India Hereditary Angioedema Consumption (2017-2022)

      • 10.4.4 South Korea Hereditary Angioedema Consumption (2017-2022)

      • 10.4.5 Pakistan Hereditary Angioedema Consumption (2017-2022)

      • 10.4.6 Bangladesh Hereditary Angioedema Consumption (2017-2022)

      • 10.4.7 Indonesia Hereditary Angioedema Consumption (2017-2022)

      • 10.4.8 Thailand Hereditary Angioedema Consumption (2017-2022)

      • 10.4.9 Singapore Hereditary Angioedema Consumption (2017-2022)

      • 10.4.10 Malaysia Hereditary Angioedema Consumption (2017-2022)

      • 10.4.11 Philippines Hereditary Angioedema Consumption (2017-2022)

      • 10.4.12 Vietnam Hereditary Angioedema Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Hereditary Angioedema Consumption (2017-2022)

      • 10.5.2 Colombia Hereditary Angioedema Consumption (2017-2022)

      • 10.5.3 Chile Hereditary Angioedema Consumption (2017-2022)

      • 10.5.4 Argentina Hereditary Angioedema Consumption (2017-2022)

      • 10.5.5 Venezuela Hereditary Angioedema Consumption (2017-2022)

      • 10.5.6 Peru Hereditary Angioedema Consumption (2017-2022)

      • 10.5.7 Puerto Rico Hereditary Angioedema Consumption (2017-2022)

      • 10.5.8 Ecuador Hereditary Angioedema Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Hereditary Angioedema Consumption (2017-2022)

      • 10.6.2 Kuwait Hereditary Angioedema Consumption (2017-2022)

      • 10.6.3 Oman Hereditary Angioedema Consumption (2017-2022)

      • 10.6.4 Qatar Hereditary Angioedema Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Hereditary Angioedema Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Hereditary Angioedema Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Hereditary Angioedema Consumption (2017-2022)

      • 10.7.2 South Africa Hereditary Angioedema Consumption (2017-2022)

      • 10.7.3 Egypt Hereditary Angioedema Consumption (2017-2022)

      • 10.7.4 Algeria Hereditary Angioedema Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Hereditary Angioedema Consumption (2017-2022)

      • 10.8.2 New Zealand Hereditary Angioedema Consumption (2017-2022)

    11 Global Hereditary Angioedema Competitive Analysis

    • 11.1 Shire plc

      • 11.1.1 Shire plc Company Details

      • 11.1.2 Shire plc Hereditary Angioedema Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Shire plc Hereditary Angioedema Main Business and Markets Served

      • 11.1.4 Shire plc Hereditary Angioedema Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 CSL Limited

      • 11.2.1 CSL Limited Company Details

      • 11.2.2 CSL Limited Hereditary Angioedema Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 CSL Limited Hereditary Angioedema Main Business and Markets Served

      • 11.2.4 CSL Limited Hereditary Angioedema Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 BioCryst Pharmaceuticals Inc

      • 11.3.1 BioCryst Pharmaceuticals Inc Company Details

      • 11.3.2 BioCryst Pharmaceuticals Inc Hereditary Angioedema Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 BioCryst Pharmaceuticals Inc Hereditary Angioedema Main Business and Markets Served

      • 11.3.4 BioCryst Pharmaceuticals Inc Hereditary Angioedema Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 iBio Inc

      • 11.4.1 iBio Inc Company Details

      • 11.4.2 iBio Inc Hereditary Angioedema Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 iBio Inc Hereditary Angioedema Main Business and Markets Served

      • 11.4.4 iBio Inc Hereditary Angioedema Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Ionis Pharmaceuticals Inc

      • 11.5.1 Ionis Pharmaceuticals Inc Company Details

      • 11.5.2 Ionis Pharmaceuticals Inc Hereditary Angioedema Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Ionis Pharmaceuticals Inc Hereditary Angioedema Main Business and Markets Served

      • 11.5.4 Ionis Pharmaceuticals Inc Hereditary Angioedema Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Pharming Group NV

      • 11.6.1 Pharming Group NV Company Details

      • 11.6.2 Pharming Group NV Hereditary Angioedema Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Pharming Group NV Hereditary Angioedema Main Business and Markets Served

      • 11.6.4 Pharming Group NV Hereditary Angioedema Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    12 Global Hereditary Angioedema Market Outlook by Types and Applications to 2028

    • 12.1 Global Hereditary Angioedema Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global C1 Esterase Inhibitor Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Kallikrein Inhibitor Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Selective Bradykinin B2 Receptor Antagonist Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Hereditary Angioedema Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Hereditary Angioedema Market Analysis and Outlook to 2028

    • 13.1 Global Hereditary Angioedema Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.2.2 Canada Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Hereditary Angioedema Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.3.2 UK Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.3.3 Spain Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.3.5 France Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.3.6 Italy Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.3.8 Finland Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.3.9 Norway Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.3.11 Poland Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.3.12 Russia Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Hereditary Angioedema Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.4.2 Japan Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.4.3 India Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Hereditary Angioedema Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.5.3 Chile Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.5.6 Peru Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Hereditary Angioedema Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.6.3 Oman Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Hereditary Angioedema Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Hereditary Angioedema Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Hereditary Angioedema Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Hereditary Angioedema Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Hereditary Angioedema

    • Figure of Hereditary Angioedema Picture

    • Table Global Hereditary Angioedema Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Hereditary Angioedema Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global C1 Esterase Inhibitor Consumption and Growth Rate (2017-2022)

    • Figure Global Kallikrein Inhibitor Consumption and Growth Rate (2017-2022)

    • Figure Global Selective Bradykinin B2 Receptor Antagonist Consumption and Growth Rate (2017-2022)

    • Figure Global Retail Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Online Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Hereditary Angioedema Consumption by Country (2017-2022)

    • Table North America Hereditary Angioedema Consumption by Country (2017-2022)

    • Figure United States Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Canada Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Mexico Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Table Europe Hereditary Angioedema Consumption by Country (2017-2022)

    • Figure Germany Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure UK Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Spain Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Belgium Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure France Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Italy Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Denmark Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Finland Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Norway Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Sweden Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Poland Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Russia Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Turkey Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Table APAC Hereditary Angioedema Consumption by Country (2017-2022)

    • Figure China Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Japan Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure India Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure South Korea Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Thailand Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Singapore Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Philippines Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Table South America Hereditary Angioedema Consumption by Country (2017-2022)

    • Figure Brazil Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Colombia Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Chile Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Argentina Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Peru Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Table GCC Hereditary Angioedema Consumption by Country (2017-2022)

    • Figure Bahrain Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Oman Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Qatar Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Table Africa Hereditary Angioedema Consumption by Country (2017-2022)

    • Figure Nigeria Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure South Africa Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Egypt Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure Algeria Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Table Oceania Hereditary Angioedema Consumption by Country (2017-2022)

    • Figure Australia Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Hereditary Angioedema Consumption and Growth Rate (2017-2022)

    • Table Shire plc Company Details

    • Table Shire plc Hereditary Angioedema Sales, Price, Value and Gross Profit (2017-2022)

    • Table Shire plc Hereditary Angioedema Main Business and Markets Served

    • Table Shire plc Hereditary Angioedema Product Portfolio

    • Table CSL Limited Company Details

    • Table CSL Limited Hereditary Angioedema Sales, Price, Value and Gross Profit (2017-2022)

    • Table CSL Limited Hereditary Angioedema Main Business and Markets Served

    • Table CSL Limited Hereditary Angioedema Product Portfolio

    • Table BioCryst Pharmaceuticals Inc Company Details

    • Table BioCryst Pharmaceuticals Inc Hereditary Angioedema Sales, Price, Value and Gross Profit (2017-2022)

    • Table BioCryst Pharmaceuticals Inc Hereditary Angioedema Main Business and Markets Served

    • Table BioCryst Pharmaceuticals Inc Hereditary Angioedema Product Portfolio

    • Table iBio Inc Company Details

    • Table iBio Inc Hereditary Angioedema Sales, Price, Value and Gross Profit (2017-2022)

    • Table iBio Inc Hereditary Angioedema Main Business and Markets Served

    • Table iBio Inc Hereditary Angioedema Product Portfolio

    • Table Ionis Pharmaceuticals Inc Company Details

    • Table Ionis Pharmaceuticals Inc Hereditary Angioedema Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ionis Pharmaceuticals Inc Hereditary Angioedema Main Business and Markets Served

    • Table Ionis Pharmaceuticals Inc Hereditary Angioedema Product Portfolio

    • Table Pharming Group NV Company Details

    • Table Pharming Group NV Hereditary Angioedema Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pharming Group NV Hereditary Angioedema Main Business and Markets Served

    • Table Pharming Group NV Hereditary Angioedema Product Portfolio

    • Figure Global C1 Esterase Inhibitor Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Kallikrein Inhibitor Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Selective Bradykinin B2 Receptor Antagonist Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hereditary Angioedema Consumption Forecast by Country (2022-2028)

    • Table North America Hereditary Angioedema Consumption Forecast by Country (2022-2028)

    • Figure United States Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Hereditary Angioedema Consumption Forecast by Country (2022-2028)

    • Figure Germany Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Hereditary Angioedema Consumption Forecast by Country (2022-2028)

    • Figure China Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Hereditary Angioedema Consumption Forecast by Country (2022-2028)

    • Figure Brazil Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Hereditary Angioedema Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Hereditary Angioedema Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Hereditary Angioedema Consumption Forecast by Country (2022-2028)

    • Figure Australia Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Hereditary Angioedema Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US